193 related articles for article (PubMed ID: 38097619)
1. Polygenic risk alters the penetrance of monogenic kidney disease.
Khan A; Shang N; Nestor JG; Weng C; Hripcsak G; Harris PC; Gharavi AG; Kiryluk K
Nat Commun; 2023 Dec; 14(1):8318. PubMed ID: 38097619
[TBL] [Abstract][Full Text] [Related]
2. Polygenic risk affects the penetrance of monogenic kidney disease.
Khan A; Shang N; Nestor JG; Weng C; Hripcsak G; Harris PC; Gharavi AG; Kiryluk K
medRxiv; 2023 May; ():. PubMed ID: 37214819
[TBL] [Abstract][Full Text] [Related]
3. Monogenic and polygenic concepts in chronic kidney disease (CKD).
Jefferis J; Hudson R; Lacaze P; Bakshi A; Hawley C; Patel C; Mallett A
J Nephrol; 2024 Jan; 37(1):7-21. PubMed ID: 37989975
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide polygenic score to predict chronic kidney disease across ancestries.
Khan A; Turchin MC; Patki A; Srinivasasainagendra V; Shang N; Nadukuru R; Jones AC; Malolepsza E; Dikilitas O; Kullo IJ; Schaid DJ; Karlson E; Ge T; Meigs JB; Smoller JW; Lange C; Crosslin DR; Jarvik GP; Bhatraju PK; Hellwege JN; Chandler P; Torvik LR; Fedotov A; Liu C; Kachulis C; Lennon N; Abul-Husn NS; Cho JH; Ionita-Laza I; Gharavi AG; Chung WK; Hripcsak G; Weng C; Nadkarni G; Irvin MR; Tiwari HK; Kenny EE; Limdi NA; Kiryluk K
Nat Med; 2022 Jul; 28(7):1412-1420. PubMed ID: 35710995
[TBL] [Abstract][Full Text] [Related]
5. Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes.
Goodrich JK; Singer-Berk M; Son R; Sveden A; Wood J; England E; Cole JB; Weisburd B; Watts N; Caulkins L; Dornbos P; Koesterer R; Zappala Z; Zhang H; Maloney KA; Dahl A; Aguilar-Salinas CA; Atzmon G; Barajas-Olmos F; Barzilai N; Blangero J; Boerwinkle E; Bonnycastle LL; Bottinger E; Bowden DW; Centeno-Cruz F; Chambers JC; Chami N; Chan E; Chan J; Cheng CY; Cho YS; Contreras-Cubas C; Córdova E; Correa A; DeFronzo RA; Duggirala R; Dupuis J; Garay-Sevilla ME; García-Ortiz H; Gieger C; Glaser B; González-Villalpando C; Gonzalez ME; Grarup N; Groop L; Gross M; Haiman C; Han S; Hanis CL; Hansen T; Heard-Costa NL; Henderson BE; Hernandez JMM; Hwang MY; Islas-Andrade S; Jørgensen ME; Kang HM; Kim BJ; Kim YJ; Koistinen HA; Kooner JS; Kuusisto J; Kwak SH; Laakso M; Lange L; Lee JY; Lee J; Lehman DM; Linneberg A; Liu J; Loos RJF; Lyssenko V; Ma RCW; Martínez-Hernández A; Meigs JB; Meitinger T; Mendoza-Caamal E; Mohlke KL; Morris AD; Morrison AC; Ng MCY; Nilsson PM; O'Donnell CJ; Orozco L; Palmer CNA; Park KS; Post WS; Pedersen O; Preuss M; Psaty BM; Reiner AP; Revilla-Monsalve C; Rich SS; Rotter JI; Saleheen D; Schurmann C; Sim X; Sladek R; Small KS; So WY; Spector TD; Strauch K; Strom TM; Tai ES; Tam CHT; Teo YY; Thameem F; Tomlinson B; Tracy RP; Tuomi T; Tuomilehto J; Tusié-Luna T; van Dam RM; Vasan RS; Wilson JG; Witte DR; Wong TY; ; Burtt NP; Zaitlen N; McCarthy MI; Boehnke M; Pollin TI; Flannick J; Mercader JM; O'Donnell-Luria A; Baxter S; Florez JC; MacArthur DG; Udler MS
Nat Commun; 2021 Jun; 12(1):3505. PubMed ID: 34108472
[TBL] [Abstract][Full Text] [Related]
6. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
[TBL] [Abstract][Full Text] [Related]
7. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions.
Fahed AC; Wang M; Homburger JR; Patel AP; Bick AG; Neben CL; Lai C; Brockman D; Philippakis A; Ellinor PT; Cassa CA; Lebo M; Ng K; Lander ES; Zhou AY; Kathiresan S; Khera AV
Nat Commun; 2020 Aug; 11(1):3635. PubMed ID: 32820175
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine in chronic kidney disease by detection of monogenic mutations.
Connaughton DM; Hildebrandt F
Nephrol Dial Transplant; 2020 Mar; 35(3):390-397. PubMed ID: 30809662
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of p.Gln368Ter Myocilin Variant and Influence of Polygenic Risk on Glaucoma Penetrance in the UK Biobank.
Zebardast N; Sekimitsu S; Wang J; Elze T; Gharahkhani P; Cole BS; Lin MM; Segrè AV; Wiggs JL;
Ophthalmology; 2021 Sep; 128(9):1300-1311. PubMed ID: 33713785
[TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of Novel Mutations in Chronic Kidney Disease (CKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Saudi Subjects by Whole-Exome Sequencing.
Alzahrani OR; Alatwi HE; Alharbi AA; Alessa AH; Al-Amer OM; Alanazi AFR; Shams AM; Alomari E; Naser AY; Alzahrani FA; Hosawi S; Alghamdi SM; Abdali WA; Elfaki I; Hawsawi YM
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36422197
[TBL] [Abstract][Full Text] [Related]
11. Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank.
Choi SH; Jurgens SJ; Weng LC; Pirruccello JP; Roselli C; Chaffin M; Lee CJ; Hall AW; Khera AV; Lunetta KL; Lubitz SA; Ellinor PT
Circ Res; 2020 Jan; 126(2):200-209. PubMed ID: 31691645
[TBL] [Abstract][Full Text] [Related]
12. NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease.
Ramanathan G; Periyasamy S; Lakkakula BV
Nephrology (Carlton); 2014 Sep; 19(9):537-41. PubMed ID: 24824375
[TBL] [Abstract][Full Text] [Related]
13. Rare genetic causes of complex kidney and urological diseases.
Groopman EE; Povysil G; Goldstein DB; Gharavi AG
Nat Rev Nephrol; 2020 Nov; 16(11):641-656. PubMed ID: 32807983
[TBL] [Abstract][Full Text] [Related]
14. How Does ADPKD Severity Differ Between Family Members?
Yeung KC; Fryml E; Lanktree MB
Kidney Int Rep; 2024 May; 9(5):1198-1209. PubMed ID: 38707833
[TBL] [Abstract][Full Text] [Related]
15. Population data improves variant interpretation in autosomal dominant polycystic kidney disease.
Mallawaarachchi AC; Furlong TJ; Shine J; Harris PC; Cowley MJ
Genet Med; 2019 Jun; 21(6):1425-1434. PubMed ID: 30369598
[TBL] [Abstract][Full Text] [Related]
16. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone synthase gene is not a major susceptibility gene for progression of chronic kidney disease in patients with autosomal dominant polycystic kidney disease.
Ramanathan G; Elumalai R; Periyasamy S; Lakkakula BVKS
Saudi J Kidney Dis Transpl; 2017; 28(3):552-557. PubMed ID: 28540892
[TBL] [Abstract][Full Text] [Related]
18. Polygenic risk score as a possible tool for identifying familial monogenic causes of complex diseases.
Lu T; Forgetta V; Richards JB; Greenwood CMT
Genet Med; 2022 Jul; 24(7):1545-1555. PubMed ID: 35460399
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early-onset and fast cyst progression.
Peces R; Mena R; Peces C; Cuesta E; Selgas R; Barruz P; Lapunzina P; Nevado J
Clin Genet; 2020 Jun; 97(6):857-868. PubMed ID: 32166738
[TBL] [Abstract][Full Text] [Related]
20. Monogenic and Polygenic Contributions to QTc Prolongation in the Population.
Nauffal V; Morrill VN; Jurgens SJ; Choi SH; Hall AW; Weng LC; Halford JL; Austin-Tse C; Haggerty CM; Harris SL; Wong EK; Alonso A; Arking DE; Benjamin EJ; Boerwinkle E; Min YI; Correa A; Fornwalt BK; Heckbert SR; ; Kooperberg C; Lin HJ; J F Loos R; Rice KM; Gupta N; Blackwell TW; Mitchell BD; Morrison AC; Psaty BM; Post WS; Redline S; Rehm HL; Rich SS; Rotter JI; Soliman EZ; Sotoodehnia N; Lunetta KL; Ellinor PT; Lubitz SA;
Circulation; 2022 May; 145(20):1524-1533. PubMed ID: 35389749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
